eczema

Person throwing piece of paper into full waste bin
Biotech

Anaptys scraps atopic dermatitis asset after ph. 2 fail

ANB032 failed to reduce eczema area and itch severity in a phase 2b trial, missing all of its endpoints.
Darren Incorvaia Dec 11, 2024 11:02am
target reach ladder climb meet win beat competition

Amgen reports first phase 3 win for $400M eczema drug

Sep 25, 2024 5:50am
Deal terminate tear up end deal scrap

Connect uncouples from Pfizer by scrapping eczema pact

Apr 17, 2024 6:38am
eczema atopic dermatitis Black African American patient skin of color

Lilly's lebrikizumab clears eczema in people with skin of color

Mar 11, 2024 9:24am
game connect

Connecting the dots: Asthma asset aces phase 2b trial

Dec 12, 2023 11:00am
game connect

California biotech Connects with Simcere in $141M licensing pact

Nov 21, 2023 11:07am